Advertisement

ADVERTISEMENT

Jolynn Tumolo

News
Dialysis Solution Recalled
09/08/2023
Jolynn Tumolo
A class II recall has been issued for more than 500,000 bottles of Dianeal Low Calcium peritoneal dialysis solution because of a lack of assurance of sterility.
A class II recall has been issued for more than 500,000 bottles of Dianeal Low Calcium peritoneal dialysis solution because of a lack of assurance of sterility.
A class II recall has been...
09/08/2023
Pharmacy Learning Network
Long-term Use of Proton Pump Inhibitors Linked With Higher Dementia Risk
News
Long-term Use of Proton Pump Inhibitors Linked With Higher Dementia Risk
09/07/2023
Jolynn Tumolo
Use of prescription proton pump inhibitors that stretched 4.5 years or longer was associated with an increased risk of dementia, according to study findings published online ahead of print in Neurology.
Use of prescription proton pump inhibitors that stretched 4.5 years or longer was associated with an increased risk of dementia, according to study findings published online ahead of print in Neurology.
Use of prescription proton pump...
09/07/2023
Neurology
News
Strong Self-Identity, Accessibility Key for Self-Management of MS
09/06/2023
Jolynn Tumolo
The intricacies of socio-ecological factors that impact how individuals with multiple sclerosis (MS) manage their lifestyles are multifaceted, often converging around two primary elements: self-identity and accessibility.
The intricacies of socio-ecological factors that impact how individuals with multiple sclerosis (MS) manage their lifestyles are multifaceted, often converging around two primary elements: self-identity and accessibility.
The intricacies of...
09/06/2023
First Report Managed Care
News
Bevacizumab Before Aflibercept for DME May Offer Major Cost Savings
09/06/2023
Jolynn Tumolo
Aflibercept monotherapy costs approximately $12,000 more than treating patients with diabetic macular edema (DME) with bevacizumab first, and then switching to aflibercept if response is suboptimal, according to a recent study.
Aflibercept monotherapy costs approximately $12,000 more than treating patients with diabetic macular edema (DME) with bevacizumab first, and then switching to aflibercept if response is suboptimal, according to a recent study.
Aflibercept monotherapy costs...
09/06/2023
First Report Managed Care
News
Study Finds No Significant Link between eGFR and DME in Latino Patients
09/06/2023
Jolynn Tumolo
There was no association between glomerular filtration rate and diabetic macular edema (DME) in a study of Latino patients with type 2 diabetes and DME.
There was no association between glomerular filtration rate and diabetic macular edema (DME) in a study of Latino patients with type 2 diabetes and DME.
There was no association between...
09/06/2023
First Report Managed Care
News
Digital Therapeutic Linked With Decreased Alcohol Use in Patients With ARLD
09/05/2023
Jolynn Tumolo
Recent studies suggest use of a digital therapeutic for patients with alcohol-related liver disease (ARLD) was associated with a significant decrease in alcohol use and a higher proportion of patients attaining alcohol abstinence.
Recent studies suggest use of a digital therapeutic for patients with alcohol-related liver disease (ARLD) was associated with a significant decrease in alcohol use and a higher proportion of patients attaining alcohol abstinence.
Recent studies suggest use of a...
09/05/2023
First Report Managed Care
News
For Patients With Depression, Engagement in Digital Interventions Appears Limited
09/05/2023
Jolynn Tumolo
Digital therapeutics for depression included 47 unique web-based interventions (as well as 10 unnamed web-based interventions), 15 mobile app interventions, 5 app-based interventions also available on the internet, and 1 CD-ROM, according to...
Digital therapeutics for depression included 47 unique web-based interventions (as well as 10 unnamed web-based interventions), 15 mobile app interventions, 5 app-based interventions also available on the internet, and 1 CD-ROM, according to...
Digital therapeutics for...
09/05/2023
First Report Managed Care
News
Subpotent Blood Pressure Drug Recalled
09/01/2023
Jolynn Tumolo
Glenmark Pharmaceuticals Inc. is recalling 1200 bottles of trandolapril and verapamil hydrochloride extended-release tablets for subpotency. According to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report, samples...
Glenmark Pharmaceuticals Inc. is recalling 1200 bottles of trandolapril and verapamil hydrochloride extended-release tablets for subpotency. According to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report, samples...
Glenmark Pharmaceuticals Inc. is...
09/01/2023
Pharmacy Learning Network
News
Anticonvulsant Recalled
09/01/2023
Jolynn Tumolo
Aurobindo Pharma USA Inc. is pulling 96 bottles of rufinamide tablets that were released prior to approval, according to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report.
Aurobindo Pharma USA Inc. is pulling 96 bottles of rufinamide tablets that were released prior to approval, according to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report.
Aurobindo Pharma USA Inc. is...
09/01/2023
Pharmacy Learning Network
News
Chemotherapy Drug Recalled
09/01/2023
Jolynn Tumolo
Baxter Healthcare Corporation is recalling 13,502 vials of bendamustine hydrochloride injection after a customer reported vials with peeling labels, according to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report.
Baxter Healthcare Corporation is recalling 13,502 vials of bendamustine hydrochloride injection after a customer reported vials with peeling labels, according to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report.
Baxter Healthcare Corporation is...
09/01/2023
Pharmacy Learning Network

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
November 1 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use